Form D · Biotechnology
Aurinia Pharmaceuticals Inc.
Victoria, A1 · CIK 0001600620
Offering snapshot reported Feb 28, 2014 · SEC filing
- Reported sold
- $52M Offering amount: $52M
- Investors reported
- 22 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 14, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 28, 2014 | Initial | $52,000,000 | No comparison | 22 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $3.49M
- Finders' fees
- $0
- Form D file number
- 021-212735
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Leerink Partners LLC | 39011 | |
| Canaccord Genuity Inc. | 1020 |
Source: Form D, filed Feb 28, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Dennis Bourgeault | Executive |
| Kurt Von Emster | Director |
| Richard M. Glickman | Director, Executive |
| Chris Kim | Director |
| Michael Martin | Director, Executive |
| Daniel Park | Director |
| Benjamin Rovinski | Director |
| Peter Wijngaard | Director |
| Donald Wyatt | Director |
| Stephen W. Zaruby | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
#1203 4464 Markham Street
Victoria, A1, V8Z 7X8
Victoria, A1, V8Z 7X8